Screener
BioCryst Pharmaceuticals BCRX Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LongTermInvestments.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total current assets | 484,683 | 404,346 |
| Long-term inventory, net | 31,945 | 23,990 |
| Property and equipment, net | 9,058 | 8,783 |
| Long-term investments | — | 61,164 |
| Right of use assets, net | 12,608 | 10,203 |
| Other assets | 19,557 | 5,672 |
| Total assets | $557,851 | $514,158 |
| Liabilities and Stockholders’ Deficit |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's equity method investments?
- BioCryst Pharmaceuticals (BCRX) reported equity method investments of $0 in Q2 2026.
- How has BioCryst Pharmaceuticals's equity method investments changed year-over-year?
- BioCryst Pharmaceuticals's equity method investments decreased by 100.0% year-over-year, from $10.1M to $0.
- What is the long-term trend for BioCryst Pharmaceuticals's equity method investments?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's equity method investments has grown at a 73.0% compound annual growth rate (CAGR), from $6.83M to $61.16M.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.
Ask your AI about BioCryst Pharmaceuticals's equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude